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Abstract 
The development of potent drugs for the control of viraemia in people living with HIV means that infected people may live a 
normal, healthy life and offers the prospect of eliminating HIV transmission in the short term and HIV infection in the long 
term. Other interventions, including the use of condoms, pre-exposure prophylaxis, treatment of sexually transmitted infections 
and behaviour change programmes, may also be effective in reducing HIV transmission to varying degrees. 
 Here we examine recommendations for when to start treatment with anti-retroviral drugs, estimate the impact that treatment 
may have on HIV transmission in the short and in the long term, and compare the impact and cost of treatment with that of 
other methods of control. We focus on generalized HIV epidemics in sub-Saharan Africa. We show that universal access to 
ART combined with early treatment is the most effective and, in the long term, the most cost-effective intervention. 
Elimination will require effective coverage of about 80% or more but treatment is effective and cost effective even at low 
levels of coverage.  
 Other interventions may provide important support to a programme of early treatment in particular groups. Condoms 
provide protection for both men and women and should be readily available whenever they are needed. Medical male 
circumcision will provide a degree of immediate protection for men and microbicides will do the same for women. Behaviour 
change programmes in themselves are unlikely to have a significant impact on overall transmission but may play a critical role 
in supporting early treatment through helping to avoid stigma and discrimination, ensuring the acceptability of testing and 
early treatment as well as compliance. 
 
                                                          
†  This paper is a development of a presentation delivered at the 3rd International HIV Treatment as Prevention (TasP) Workshop held in Vancouver, BC, 
Canada, April 21 to 25, 2013 and in part at the 7th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-limited 
Settings, held in Dakar, Senegal, May 14 to 17, 2013. 
Introduction 
Treatment guidelines for people living with HIV 
increasingly advise people to start anti-retroviral therapy 
(ART) sooner rather than later after infection. However, 
treatment guidelines have changed significantly over the 
past fifteen years and there are differences among country 
guidelines leading to uncertainty as to how to interpret and 
act on the advice.  
 Here we examine historical changes in the treatment 
guidelines and argue that CD4+ cell counts should no 
longer be used as a condition for starting anti-retroviral 
therapy (ART). We develop a simple model to determine 
the impact that each of several interventions could have on 
HIV-transmission. We investigate the impact of early 
treatment, use of condoms, pre-exposure prophylaxis, 
treatment of sexually transmitted infections and behaviour 
change programmes on the incidence of HIV if given to 
individual people and at a population level in the short and 
the long term. 
 We show that the elimination of HIV, using currently 
available methods of control, will depend primarily on 
early treatment but other methods of control will provide 
additional support and will provide an important degree of 
protection for some groups at high risk of infection. 
Finally, we examine the relative impact and costs of the 
various interventions and briefly discuss the affordability 
of stopping HIV. 
Changing guidelines 
Several international organizations, including the 
International AIDS Society (IAS), the European AIDS 
Clinical Society (EACS), the World Health Organization 
(WHO), and many countries1 have developed guidelines 
on when to start ART. The guidelines have changed over 
time and vary among countries.2 A particularly important 
change was made in 2002 when the WHO advised low- 
and middle-income countries to start adults on ART only 
when their CD4+ cell count was below 200/μL. 
 In the year 2000 the International AIDS Society (IAS) 
and the Department of Health and Human Services 
(DHHS) used data from the Multi-Centre AIDS Cohort 
Study (MACS)3 (Figure 1) to assess the probability that a 
person infected with HIV would develop an AIDS related 
condition in the next three years. 
 
 
 
 
 
 
 
 
 
Figure 1. Probability of developing an AIDS related condition 
within 3 years as a function of viral load and CD4+ cell count4 
from the MACS cohort.3 
 As expected, people with low viral loads are unlikely 
to develop AIDS related conditions especially if they also 
have a high CD4+ cell count. The data in Figure 1 are 
replotted in Figure 2 as an area plot. The inset numbers 
give the probability of developing an AIDS related 
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condition. For example, people whose viral load and 
CD4+ cell counts puts them on the line dividing the green 
and yellow areas have a 5% probability of developing an 
AIDS related condition in the next three years. The brown 
dots in Figure 2 are from a cross-sectional survey of HIV-
positive young men in Orange Farm, South Africa in the 
year 2000 (Bertran Auvert, personal communication) and 
show the range of viral load and CD4+ cell counts in a 
typical community in South Africa. 
 In Figure 2, top right, the DHHS recommendations for 
starting ART4 in the year 2000 are indicated by the blue 
lines. Everyone with a viral load above 10k/mL, to the 
right of the blue lines, or with a CD4+ cell count below 
500/μL, below the blue lines, were advised to start ART. 
The brown dots show that in Orange Farm, in the year 
2000, 90% of HIV-positive young men would have been 
eligible for ART under the DHHS guidelines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Top left: The data in Figure 1 replotted as an area plot. 
The brown dots are viral load and CD4+ cell counts for young 
men in Orange Farm, South Africa in the year 2000 (Bertran 
Auvert, personal communication). Top right: DHHS 2000 
guidelines;4 people to the right of and below the blue lines should 
start ART. Bottom left: IAS 2000 guidelines;5 people to the right 
of and below the brown lines should start ART; those between 
the brown lines should consider starting ART. Bottom right: 
WHO 2002 guidelines;6 people below the purple line should start 
ART. Inset numbers: probability (%) of developing an AIDS 
related condition in the next three years. 
 In Figure 2, bottom left, the IAS recommendations for 
starting ART5 also in the year 2000 are indicated by the 
brown lines. Everyone with a viral load above 30k/mL, to 
the right of the brown lines, or with a CD4+ cell count 
below 350/μL, below the brown lines, was advised to start 
ART. Everyone with a viral load and CD4+ cell count that 
puts them between the lines should consider starting 
therapy. The brown dots show that in Orange Farm, in the 
year 2000, 90% of HIV-positive young men would have 
been eligible for ART under the IAS guidelines. 
 In Figure 2, bottom right, the WHO recommendations 
for starting ART, in the year 2002, are indicated by the 
purple line.6 They do not include a viral load cut-off and 
recommend only that people with a CD4+ cell count 
below 200/μL were advised to start ART. The brown dots 
show that in Orange Farm, in the year 2000, 10% of HIV-
positive young men would have been eligible for ART 
under the WHO guidelines. It is important to note that the 
WHO guidelines also recommend treatment for all people 
in WHO clinical stages III or IV. We can estimate the 
number of people who will develop an AIDS related 
opportunistic infection before they reach a CD4+ cell 
count of 200/μL from data on the incidence of various 
opportunistic infections as a function of CD4+ cell 
counts.7 These data suggest that approximately 20% of 
people infected with HIV will develop AIDS related 
conditions including Pneumocystis carinii pneumonia, 
Mycobacterium avium complex infection, toxoplasmosis, 
cytomegalovirus, or a fungal infection before their CD4+ 
cell count falls to 200/μL. Furthermore, about half of those 
who develop TB will do so before their CD4+ cell count 
reaches 200/μL.8 
 The effect of the changes introduced by WHO in 2002 
was to reduce the proportion of HIV-positive young men 
in Orange Farm who would have been eligible for 
treatment from 90% to 10% whereas one might have 
expected a ‘public health approach’ to be concerned with 
ways to expand, not reduce, treatment coverage. 
 Many countries continue to follow the WHO 2002 
guidelines and in 2012 about 30% of countries surveyed 
recommended ART only for those asymptomatic people 
with a CD4+ cell count below 200/μL and about another 
60% of countries surveyed recommended ART only for 
those asymptomatic people with a CD4+ cell count below  
350/μL.1  
 After the year 2002 most of the formal guidelines have 
steadily increased the CD4+ cell count at which people are 
advised to start treatment. In 2013 the IAS9 recommended 
that ‘All adults with HIV infection should be offered ART 
regardless of CD4 cell count, based on …data [showing] 
that all patients may benefit from ART …[and] that ART 
reduces the likelihood of HIV transmission [and] provides 
clinical benefits’. In 2013 the DHHS10 recommended 
‘ART … for all HIV-infected individuals to reduce the risk 
of disease progression… [and]… for the prevention of 
transmission’. In both sets of guidelines it was felt that 
early ART was in the best interests of the individual 
patient and would have the added benefit of preventing 
further transmission. 
 Now, in 2013, the WHO recommends treatment for all 
people whose CD4+ cell counts is less than 500/μL and all 
HIV-positive people with TB, Hepatitis B, who are 
pregnant, or under the age of five years, irrespective of 
CD4+ cell count. The new guidelines are close to where 
they were in the year 2000 but without the viral load 
condition.11 Data on the distribution of CD4+ cell counts 
in HIV-negative people12 suggest that about 80% of all 
those currently infected with HIV and not on ART will 
have a CD4+ cell count below 500/μL. If we include the 
other groups of people that should start treatment 
irrespective of their CD4+ cell count then about 90% of all 
HIV positive people are currently eligible for ART. Since 
CD4+ cell counts have very little prognostic value at an 
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individual level,12 considerable savings in time, human 
resources and money could be had by abandoning the use 
of CD4+ cell counts for deciding on when to start ART. 
 If there is a need to triage people in order to treat those 
at greatest risk first, the sensible way to do this would be 
on the basis of each person’s viral load. Individual CD4+ 
cell counts can vary by an order of magnitude within 
populations,12 the mean CD4+ cell count can vary by a 
factor of two between populations,12 and survival is 
independent of the initial CD4+ cell count.12,13 CD4+ cell 
counts therefore have very little prognostic value except in 
that unfortunate circumstance when the count is very low 
by which time an infected person is likely to be in WHO 
clinical stages III or IV and in need of immediate 
treatment anyway. People with a high viral load, on the 
other hand, have a greatly reduced life expectancy14 and 
are much more infectious than those with a low viral 
load.15 Where the availability of anti-retroviral drugs is 
limited, giving preference to people with high viral loads 
would have the greatest benefit for individual patients and 
the greatest impact on transmission.16 
Ending the epidemic 
Given that early ART is in the best interests of individual 
patients the question arises as to role of early treatment in 
ending the epidemic of HIV. Other ways of reducing 
transmission have been studied including condom 
promotion (CP), pre-exposure prophylaxis (PreP), medical 
male circumcision (MC), treatment of other sexually 
transmitted infections (STI), and behaviour change 
programmes (BC). Each of these could be used singly or in 
combination and we consider the contribution that each of 
them might make to ending the epidemic. 
Table 1. Incidence rate ratios (IRR) for treatment-as-prevention 
(TasP), condom promotion (CP), pre-exposure prophylaxis 
(PreP), medical male circumcision (MC), treatment of sexually 
transmitted infections (STI), and behaviour change programmes 
(BC). Trial conditions: IRR values obtained from trials; 
Coverage: IRR allowing for estimated coverage given in Figure 
3B; Long term: impact on long term steady state incidence 
allowing for non-linearities and heterogeneity assuming a steady 
state prevalence of 16% and R0 = 4.5 (Appendix 2). Exp.: 
expected values; ‘Low’ and ‘High’: 95% confidence limits. 
 Trial conditions Coverage Long-term 
 Exp. Low High Exp. Low High Exp. Low High
TasP 0.003 0.000 0.022 0.202 0.200 0.218 0.208 0.197 0.300
CP 0.128 0.040 0.407 0.564 0.520 0.704 0.837 0.806 0.911
MC 0.400 0.310 0.490 0.816 0.778 0.850 0.953 0.940 0.963
PreP 0.430 0.321 0.575 0.772 0.729 0.830 0.938 0.922 0.957
STI 0.883 0.762 1.024 0.907 0.810 1.019 0.978 0.951 1.004
BC 0.948 0.810 1.111 0.959 0.848 1.089 0.991 0.962 1.017
TasP: based on a randomized controlled trial (RCT),17 a meta-analysis18 
and data on viral load and transmission.15 CP: comparing ‘always’ v. 
‘never’ used condoms in 12 studies;19 PreP: four RCTs20-23 excluding 
those stopped for futility;24,25 MC: three RCTs;26-28 STI: three 
community RCTs;29-31 BC: ten community RCTs.32 
Projecting the impact 
We first establish the magnitude of the control problem, 
that is to say the degree to which transmission should be 
reduced in order to reduce the case reproduction number, 
R0, to less than 1.33 
 For countries in sub-Saharan Africa the value of R0 can 
be estimated from the initial doubling time of the 
prevalence of HIV and the life expectancy of people 
infected with HIV but not on ART. This gives a median 
value of 4.5 (80% within 2.6−6.3; range 1.6−9.5).34 To 
eliminate HIV in half the countries of sub-Saharan Africa 
transmission must be reduced by 4.5 times, or by 78%, and 
to eliminate HIV in 90% of the countries transmission 
must be reduced by 84%. 
The impact of interventions 
Trials of the different interventions have been done and the 
results are summarized in Table 1 and shown in Figure 3A. 
The result for TasP is an estimate based on the relationship 
between transmission and viral load15 and is consistent 
with the results of the HPTN 052 trial17 and a meta-
analysis.18 The result for condom use is an average across 
12 groups of people who said that they always uses 
condoms compared to those that said that they never used 
condoms.19 The result for PreP is from four randomized 
controlled trials (RCTs)20-23 but excluding the Fem-PreP24 
and Voice trials25 which were stopped for reasons of 
futility, probably because they were unable to achieve 
sufficiently high levels of compliance.35 The result for the 
impact of behaviour change interventions is based on ten 
community-RCTs.32  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The incidence rate ratio for: people on TasP; people 
who ‘always’ use condoms (CP); for men who are circumcised 
(MC); people on PreP; for the treatment of other sexually 
transmitted infections (STI); and for behaviour change 
programmes. A: results from trials (see text for further details); 
B: allowing for the effective coverage levels indicated; C: the 
reduction in the long-term incidence in South Africa with R0 = 
5.8 and the current adult prevalence of 16%. 
 For the treatment of sexually transmitted infections the 
impact is measured in the whole population among which 
only some people have a sexually transmitted infection. If 
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the reduction in the individual level of transmission is ρ 
and the prevalence of STIs is P, then the average 
reduction, r, would be r = ρ P + (1−P). We can calculate 
the reduction in the individual level of transmission if one 
person is treated from the reduction in risk in the whole 
population if we know the prevalence of curable STIs.36 
The estimated value of ρ is given in Figure 3A. In the case 
of behaviour change interventions we assume that the 
individual risk reduction is equal to the overall level of 
risk reduction. 
 To assess the short and long term population level 
impact and cost of the different interventions we discount 
the impact of the trials to allow for the effective coverage, 
including both coverage and compliance, as shown in 
Figure 3B. Here we assume that under TasP one can 
achieve an effective coverage of 80%; this allows for a 
testing coverage of 85% and annual testing, which should 
eliminate 90% of transmission in those tested. In the case 
of condom promotion we assume, perhaps optimistically, 
that people can be persuaded to use condoms in half of all 
sexual encounters. In the case of male circumcision some 
men will already be circumcised while others may refuse 
to be circumcised. Since the focus of PreP would be on 
people at especially high risk we assume that about 40% of 
sexual encounters are covered by PreP; in concentrated 
epidemics UNAIDS estimates that less than half of all 
transmission events are in key populations at high risk of 
infection. We assume that the effective circumcision 
coverage may reach 50% of all sexually active men and 
we allow for the fact that male circumcision protects men 
but not women.37 For sexually transmitted infections we 
assume that treatment reduces the prevalence of STIs by 
80%; the reason why the impact is small even if those with 
an STI are at very high risk of infection, is that typically 
only about 10%36 of adults may have a sexually 
transmitted infection at a given time. In the case of 
behaviour change programmes we assume that coverage is 
80%. 
 Finally we wish to estimate the long term impact of the 
various interventions assuming that the epidemic reaches a 
new steady state allowing for non-linearities in the 
relationship between transmission and prevalence and for 
heterogeneity in sexual activity (Appendix 1). In Figure 
3C we use the estimated increase in α, the rate at which 
people start treatment under TasP, and the estimated 
declines in λ, the reduction in the risk of infection for the 
other interventions, to estimate the expected steady-state 
incidence that would be achieved if each of the various 
interventions was implemented according to the effective 
coverage assumptions in Figure 3B. Figure 3C then shows 
the importance of the non-linearity in the impact of any 
intervention as a function of the reduction in transmission. 
Economics of control 
Of the order of US$16 billion per year is currently being 
spent on understanding and dealing with the epidemic of 
HIV/AIDS in low- and middle-income countries.38 
Expanding treatment and prevention efforts will demand 
significant investments, both financial and social, and we 
need to consider the economics of control. We first 
consider the cost-effectiveness of the available 
interventions and then refer briefly to the question of 
affordability since all interventions must be paid for. 
Cost 
We assume that the costs associated with each of the 
interventions are as follows. 
1. TasP: $250 per person per year for drugs, $250 per 
person per year for support and $5 per test (Appendix 
2). 
2. PreP: $1 per day and $5 per monthly test;39,40 
3. MC: $50 per circumcision;41,42 
4. STI: $20 per treatment;43 
5. BC: $0.3 per person reached per year.44 
 Effectiveness can be measured in many ways including 
direct disease outcomes such as prevalence, incidence, 
mortality or life expectancy, but also social and economic 
outcomes such as community coherence, reduction in 
stigma, increases in employment, contribution to the gross 
national product and so on. Since we are concerned with 
controlling and eventually eliminating HIV we will focus 
on the impact on HIV incidence. We do not include the 
considerable cost-savings that will accrue through 
avoiding hospitalization, medical costs for people who 
would otherwise have developed AIDS-related conditions 
or the economic benefits of maintaining a healthy and 
productive workforce. This analysis is conservative in 
relation to costs and benefits. 
 In estimating the costs and impact of intervening with a 
single person we assume that the background incidence 
and prevalence are unchanged and use the reduction in the 
risk of infection as measured in the trials (Figure 3A and 
Table 1).  
 For the short term, which we may consider to be the 
first year after full implementation, we make the same 
assumptions but allow for estimated levels of coverage 
(Figure 3B and Table 1). 
 In the long term, say ten years after reaching full 
coverage, we assume that the epidemic is in a new steady 
state. The point is that people infected with HIV must 
either be started on ART or they will die. Since the 
financial cost to society of letting them die is, in almost all 
countries, greater than the cost of maintaining them on 
ART (Appendix 3), we assume that under interventions 
other than TasP HIV-positive people are started on ART at 
a late stage of their disease so that they are kept alive and 
are no longer infectious but the intervention has no impact 
on transmission. We must then account for the cost of 
keeping all HIV-positive people alive once they start ART 
in all of the interventions. 
Costs and effects 
Details of the cost-benefit calculations are given in 
Appendix 4 and the impact of each intervention in relation 
to its cost is shown in Figure 4 for each intervention in 
South Africa assuming an initial, steady state prevalence 
among adults of 16% and a value of R0 equal to 5.8. The 
shaded areas indicate the cost-benefits ratios. For example, 
the line dividing the areas shaded green and blue would 
imply a cost of $100 per adult per year to reduce the 
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incidence to zero, or a cost of $50 per adult per year to 
reduce the incidence by 50%. 
 If individual people are started on ART the cost and the 
impact on an individual person’s risk of infection is shown 
in Figure 4A. The most effective interventions are TasP 
and using condoms since these have the greatest impact at 
an individual level. The most cost effective intervention is 
treating sexually transmitted infections in those that 
present with such an infection but this only applies to the 
relatively small proportion of people who have a sexually 
transmitted infection at a given time. PreP is the third most 
effective but is the least cost effective. For PreP we 
assume that people are taking or using anti-retroviral drugs 
every day even though they may only be occasionally at 
risk. If a microbicide could be applied only when the 
person is expecting to have sex, then the costs could be cut 
by an order of magnitude. This would reduce the cost of 
PreP to something like the cost of using condoms or male 
circumcision. Behaviour change programmes are very cost 
effective but the effect is very small so they are unlikely to 
have an impact.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The HIV incidence rate ratio, with and without each intervention, plotted against the cost of various interventions in South Africa 
assuming an initial steady state prevalence of 16% and a value of R0 equal to 5.8. The incidence rate ratio is normalized to the initial 
incidence so that 1 corresponds to an incidence of 1.6% per year.  The shaded areas indicate benefits per unit cost for fixed cost-benefit ratios 
(see legend). A: the costs and benefits of making the interventions available to individual people; B: the short term costs and benefits of each 
intervention assuming the coverage rates indicated in Figure 3; C: the long term costs and benefits of each intervention. D: as C but including 
the costs of maintaining people on ART for life assuming they start treatment just before they would otherwise have died. MC: male 
circumcision; BC: behaviour change; PreP; Pre-exposure prophylaxis: CP: condom promotion; STI: treating sexually transmitted infections; 
TasP: Treatment-as-prevention. In C and D the numbered dots indicate percentage levels of effective coverage under TasP.  
 Considering the impact of each intervention at a 
population level, but only in the short term which we 
consider to be the first year after full implementation, we 
need to allow for the levels of coverage and compliance, 
discussed in the text and indicated in Figure 3. For male 
circumcision we also have to allow for the fact that it 
protects men but not women. In this case the costs and the 
benefits are reduced in all cases but the impact per unit cost 
remains more or less the same (Figure 4B). TasP, at 80% 
coverage and compliance, still has the greatest impact and 
the impact per unit cost is among the best while PreP 
remains the least cost-effective but subject to the caveats 
noted in the previous paragraph concerning the frequency 
of use. 
 Considering the long term costs and benefits of each 
intervention we allow for the non-linear relationship 
between reductions in transmission and reductions in the 
steady state prevalence (Appendix 1). We start by 
excluding the cost of letting people die without ART 
(Figure 4C). Since TasP alone has the potential to end the 
epidemic of HIV if R0 is reduced below the critical value of 
1, the long term costs and benefits for TasP depend 
critically on the levels of coverage and compliance that can 
be reached. In Figure 4C we plot the costs and benefit for 
A                                                                       B 
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effective coverage of TasP ranging from 0 to 80% (green 
dots in steps of 10%). TasP still has the greatest potential 
impact on incidence provided the coverage is greater than 
about 50%. 
 The major long term cost arises from the need to 
maintain those that are infected with HIV on ART for life 
remembering that letting them die will cost even more. In 
Figure 4D we plot the results in Figure 4C but including the 
long term costs of maintaining all HIV-positive people on 
ART assuming that they start ART just before they would 
otherwise have died. The cost of TasP is unchanged since it 
is assumed that everyone is maintained on ART for life. 
The cost of PreP is much the same because the major cost is 
the provision of drugs to HIV-negative people. TasP at 
about 40% effective coverage has the same impact and 
cost-benefit as condom promotion, at 20% has the same 
impact as male circumcision, at 10% has the same impact 
as treating sexually transmitted diseases and at 5% has the 
same impact as behaviour change programmes. 
Discussion 
Ethics of early treatment 
In their 2002 guidelines for starting ART the WHO noted 
that ‘the resolve of the international community to address 
this appalling disparity between treated and untreated, 
between rich and poor, is stronger than ever. The world 
recognizes the pressing moral, social, political and 
economic need to expand access to antiretroviral therapy to 
many more millions of people living with HIV/AIDS as 
soon as practicable. … Countries are encouraged to adopt a 
public health approach in order to facilitate the scale-up of 
ARV use in resource-limited settings. This means that 
antiretroviral treatment programmes should be developed 
and that ARV treatment should be standardized’. The 2002 
WHO guidelines continue: ‘The recommendation to start 
treatment in asymptomatic patients only when the CD4 
count drops below 200/μL takes account of the following 
major unanswered question relating to ART: when should 
treatment be initiated in the setting of established infection 
among asymptomatic HIV-positive persons? While 
beginning therapy before the CD4 cell count falls below 
200/μL clearly provides clinical benefits, the actual point 
above 200/μL at which to start therapy has not been 
definitively determined.’ One might have argued that since 
‘beginning therapy before the CD4 cell count falls below 
200/μL clearly provides clinical benefits’ one should rather 
have recommended starting earlier and if evidence that 
starting later became available, one could then have 
recommended starting later. It is unfortunate that adapting a 
public health approach led to considerably fewer people 
being eligible to start treatment. 
 Given the current recommendations of the IAS and the 
DHHS, both based on extensive and detailed analyses of 
the risks and benefits to individual patients as well as the 
likely impact on transmission, it is clear that early ART will 
keep people alive, stop them from developing AIDS related 
infections, stop them from infecting their partners and has 
the potential to end the epidemic. Taking into account the 
most recent recommendations of the WHO11 it would be 
unethical and in violation of the Hippocratic Oath to deny 
ART to anyone infected with HIV on the basis of their 
CD4+ cell count.  
Affordability 
In addition to the costs and the cost-effectiveness it is 
important to consider the affordability of eliminating HIV. 
This depends on the size of the epidemic in each country, 
the wealth of that country and the overall cost if it proves to 
be necessary to receive donor funding. In a previous study 
we therefore compared the cost of maintaining every HIV-
positive person in each country in sub-Saharan Africa on 
ART with the gross domestic product (GDP) of that 
country.45  The country that is least able to afford universal 
ART is Malawi where the cost would amount to just less 
than 8% of GDP and there are four other countries for 
which the cost would exceed 5% of GDP: Lesotho, 
Zimbabwe, Mozambique and Burundi. Interestingly, 
Malawi already has one of the best ART programmes in the 
world but these five countries will clearly need 
international assistance to deal with the epidemic. 
However, the total cost for all five countries would only 
amount to US$1.4 billion so that the international 
community could easily afford to provide the necessary 
support. In a further six countries, Uganda,  the Central 
African Republic, Tanzania, Zambia, Swaziland and  
Kenya the cost of universal ART would be between 2% and 
5%  of GDP45 and they too would need some outside 
support.  For these eleven countries the total cost of 
universal ART would amount to US$3.4 billion still 
affordable by the international community especially with 
significant input from national governments.  All the 
remaining countries in Africa could afford to pay for 
universal ART from their own budgets. It is worth noting 
that in all but two of the remaining 25 countries military 
expenditure is currently greater than the cost of universal 
access to ART for all of  their citizens.45 
Conclusions 
In high prevalence settings with generalized epidemics the 
control of HIV must rely primarily on TasP for the benefit 
of infected people, to have the greatest impact on the 
population level incidence of HIV, and to get the greatest 
impact for the least cost. 
 Ensuring the availability and accessibility of condoms is 
important both for individuals but also at a population level 
and this may be especially important for those that believe 
themselves to be a risk but are unable to protect themselves 
in other ways. 
 Sexually transmitted infections should be treated in their 
own right as part of a programme of sexual health in the 
public sector and, for those that are treated as well as for 
their partners, the reduction in the risk of acquiring HIV 
will be substantial and very cost-effective. 
 PreP is more contentious. At an individual level PreP 
will provide a significant level of protection. However, 
PreP is likely to be less cost-effective than the other 
interventions. We have assumed here that PreP would be 
used daily whereas vaginal microbicides, for example, may 
only be used before and after a sexual encounter, which 
would reduce the costs considerably. Especially for women 
at high risk, including commercial sex-workers, young 
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adolescent women when the incidence of infection is high, 
and women who believe that they may be at risk from their 
partners but cannot negotiate condom use with their 
partners, PreP would be advised. 
 Behaviour change programmes in themselves are not 
effective. However, there will always be an important need 
for psychosocial interventions to support the other 
interventions, including TasP, in order to deal with stigma 
and discrimination, to avoid behaviour change 
disinhibition, to ensure compliance and to mobilize 
communities. Furthermore, the case of Zimbabwe raises an 
important question. The incidence of HIV in Zimbabwe 
began to fall precipitously after 199246 for reasons that 
remain unclear. At that time, ART was not available in 
Zimbabwe and there is no reason to believe that the natural 
history of HIV was any different from that in the 
neighbouring countries. The decline in HIV in Zimbabwe 
must have been because of changes in behaviour but the 
problem is to know what those changes were and why they 
were so significant in Zimbabwe but not in the 
neighbouring countries, with the possible exception of Tete 
Province in Mozambique. 
 This analysis is based primarily on the generalized 
epidemics in sub-Saharan Africa with a focus on South 
Africa where R0 = 5.8 and the steady state prevalence in 
adults is 16%. However, R0 varies among countries34 
making elimination easier in some countries than in others. 
Furthermore, the steady state or in some cases the peak 
prevalence of HIV also varies among countries47 and this 
will affect the relative costs and benefits. Where the 
prevalence is very low, as is the case in the Hindi speaking 
states of north India,48 the cost of testing all adults would 
greatly exceed the cost of providing infected adults with 
ART. In this case contact tracing or provider initiated 
counselling and testing would be more effective and 
considerably cheaper than universal routine testing. In 
countries such as Vietnam where the prevalence varies 
from about 40% in intra-venous drug users to less than 
0.4% in ante-natal clinic women, different strategies may 
have to be developed for finding and testing people in the 
different groups.49 
 It is clearly in the best interests of individual people 
infected with HIV to start ART as soon as possible. This 
will have the greatest impact on the epidemic and will be 
the most cost-effective way of controlling the spread of 
HIV. Any national prevention plan must be built around a 
programme of early treatment. Other interventions should 
also be used but in a sensible and appropriate manner. The 
use of condoms provides good protection and they must be 
easily and readily available for all those who wish to use 
them. Sexually transmitted diseases should be treated as a 
public health problem in their own right and treating 
sexually transmitted diseases will greatly reduce the risk 
that individuals face. When people are tested for HIV they 
should also be tested for other STIs and vice versa. PreP 
offers significant levels of protection and should be made 
available, wherever possible, to vulnerable people including 
sex workers and possibly adolescent girls who are sexually 
active. Male circumcision gives a significant degree of 
protection for life to individual men and this must be 
available for all those that want it. The results of rigorous 
trials of behaviour change programmes have been very 
disappointing. But even if behavioural and social 
interventions do not have a direct impact they will play an 
essential role in persuading people of the benefits of early 
treatment, in ensuring that those on treatment are fully 
compliant and that behavioural disinhibition does not 
compromise the benefits of early treatment. Furthermore 
the Zimbabwe conundrum remains46 and suggests that large 
scale behaviour change is possible and that this can have a 
dramatic effect on the epidemic. 
 It is in the best interests of individual people infected 
with HIV that they start ART as soon as they become 
infected. A programme of early treatment will lead to the 
greatest reduction in the prevalence and incidence of ART 
and offers the only way to eliminate HIV. With good 
coverage and adherence a programme of early treatment is 
also the most cost-effective intervention. The primary 
objective of HIV control programmes in generalized 
epidemics must be to start as many infected people on ART 
as soon as possible after they become infected. Other 
interventions should be used to support this primary 
intervention. Male circumcision should be available to all 
young men who want it. Condoms must be readily available 
for all who need them. PreP should be available to HIV-
negative people who are at high risk of infection. 
Behavioural interventions should focus on ways to mobilize 
communities around the need for early treatment, counter 
stigma and discrimination, and ensure high levels of 
support and adherence for those that are on ART. We have 
the means with which to eliminate HIV; what remains is the 
need to mobilize political support and commitment 
nationally and internationally to finally bring the epidemic 
to an end. 
Appendix 1. Modelling control 
Dynamic model 
In Appendix 1 we develop a simple dynamical model of 
HIV infection, in which we assume that everyone starts 
taking ART either soon after they are infected, under TasP, 
or just before they die under the other interventions. The 
model includes people who are susceptible to HIV, infected 
with HIV, or on ART. We can intervene in two ways, either 
by reducing transmission or by starting people on ART and 
reducing the size of the infector pool. 
 In this model people who would otherwise have died are 
started on ART. Then we have the following equations for 
the rate of change of s, the proportion of susceptible people 
(sensu Newton), 
 s si aλ ν= − +i  1 
for the rate of change of i, the proportion of infected 
people, not on ART, 
 i si iλ α= −i  2 
and for the rate of change of a, the proportion of people 
who would have died but are started on ART 
 a i aα ν= −i  3 
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where λ is the transmission parameter, α is the rate at 
which people start ART, and ν is the rate at which people 
on ART die. If people do not start ART we set ν = 1/τ, 
where τ is the life expectancy of people infected with ART 
but who do not start treatment. In this case a is the number 
of life-years lost because people were not started on ART. 
We then have  
 0R λα=  4 
where λ is the transmission parameter, which we can 
reduce, and α is the rate at which people start ART, which 
we can increase. Setting the left hand side of Equations 1 to 
3 equal to zero at the steady state 
 i aα ν=  5 
 s αλ=
 6 
 1s i a+ + =  7 
so that 
 ( )1 1iα αλ ν+ + =  8 
 ( )( ) 0 0
1 1
1
Ri
R
α
λ
α
ν
ν
ν α
−
−
= = ×
++
 9 
 a iα
ν
=  10 
and the incidence of infection in  is 
 in si iλ α= =  11 
 If ν → ∞ Equation 9 reduces to the usual expression for 
a simple susceptible-infected model. For a given value of 
R0 Equation 9 will overestimate the steady state prevalence 
because of heterogeneity in sexual behaviour. The simplest 
way to allow for this is to assume that there are two groups 
of people; one group is at risk according to Equations 1 to 
11, the other group is at no risk. We can then let the 
prevalence of those at no risk be n . The measured 
prevalence before we start the interventions so that no-one 
is on ART, P must be equal to the prevalence measured as a 
proportion of all those at risk, infected with HIV and at no 
risk. Since we want the initial prevalence to be 
 iP
s i n
=
+ +
 12 
we have 
 in s i
P
= − −  13 
Starting from the initial prevalence, P, we calculate the 
initial incidence, 
 I Pα=   14 
and the initial number on ART or who are dead but would 
have been alive without ART 
 A Pα
ν
=  15 
 We now consider the intervention, after it has reached a 
new steady state, and include those on ART. When we 
change either the transmission parameter λ or the rate at 
which people start ART the prevalence new steady state 
prevalence, P , is 
 iP
s i n
=
+ +
    16 
calculating s  and i from Equations 6, 9 and 10, but 
keeping n n=  since the number of people not at risk 
should not change. We then calculate A  from Equation 15. 
Appendix 2: Note on the costs of ART 
Recent studies have estimated the cost of providing ART in 
PEPFAR programmes in Uganda at US$843 per person per 
year50 and of providing ART in Zambia at US$556 per 
person per year.51 The price of anti-retroviral drugs 
continues to fall and the South African government can 
now purchase fixed-dose combination therapy for less than 
US$100 per person per month.52 In a study in Malawi the 
cost of a rapid HIV test was US$3.50.53 
Appendix 3: Cost estimates 
In the long term, say 10 years after intervening with a 
particular programme, the epidemic will reach a new steady 
state and we calculate the annual cost of maintaining the 
prevalence at the new steady state and compare this with 
the reduction in the annual number of new infections 
between the initial and final steady states. Those people that 
do get infected with HIV will die if they do not start ART. 
If they start ART when their CD4+ cell count is very low 
this will keep them alive but will not affect overall 
transmission, since those on ART will not infect others. For 
each intervention we include the cost of maintaining those 
that are infected with HIV on ART for the rest of their 
lives. 
 Since AIDS kills young adults there is a substantial cost 
to society of letting people die. When a young adult, aged 
20 to 30 years dies, society has paid to educate them, 
shelter them and provide them with health care. The social 
contract is that they should then work for the next thirty 
years to pay society back for the money that has been 
invested in them.54 For countries in sub-Saharan Africa the 
median Gross National Product per capita  is US$1,498 
(US$752−US$6,629: 80% range), the median Gross 
National Income per capita is US$645 (US$340 to 
US$4,220: 80% range).45 The cost of keeping a person on 
ART is estimated to be about US$500 per year so that if we 
let the cost of an AIDS death equal the cost of keeping that 
person alive on ART the calculations will be conservative 
as regards cost in almost all of sub-Saharan Africa. We 
therefore assume that everyone starts ART either early 
under TasP or just before they would have died under other 
interventions. 
Appendix 4: Cost-benefit calculations 
Treatment as Prevention 
Let the cost of first finding and then keeping one person on 
ART for one year be CART. If the prevalence of infection is 
PHIV then it will take, on average, 1/PHIV tests per year to 
find one person infected with HIV and the cost will be 
CTest(1−PHIV)/PHIV. The cost of putting all HIV-positive 
people on ART for one year is 
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 ( )1TasP ART HIV Test HIV TestC C P C P T= + −  17 
where TTest is the test interval in years and Equation 17 
holds when estimating the individual and the short-term 
impact. 
 In the short term the cost of testing will exceed the cost 
of keeping a person on ART for one year when 
 Test TestHIV
ART Test Test
C TP
C C T
=
+
 18 
if the cost of a test is $5, the cost of keeping a person on 
ART for one year is $500, and testing is done once a year, 
the cost of testing will exceed the cost of ART for one year 
when the prevalence is less than 1%. However, if testing 
were done monthly, say, the cost of testing will exceed the 
cost of ART when the prevalence is less than 12%. When 
we consider the population level effect we allow for the 
coverage and compliance assumptions in Figure 3B 
 In the long-term the number of people on ART will be, 
equal to the prevalence of HIV times the rate at which 
people are tested for HIV divided by the rate at which 
people on ART die (Equation 15, Appendix 1). For the 
model in Appendix 1 this will be equal to the life 
expectancy on ART divided by the test interval so that  
 ( )( )
*
*1
TasP ART HIV ART Test
Test HIV Test
C C P L T
C P T
=
+ −
 19  
where we calculate the long-term steady state prevalence, 
*HIVP , using Equation 16 in Appendix 1. In the long term 
the cost of testing will exceed the cost of keeping a person 
on ART for one year when 
 * Test TestHIV
ART ART Test Test
C TP
C L C T
=
+
 20 
and if the life expectancy on ART is 30 years then the 
critical prevalence will be 0.03%. 
Condom promotion 
The cost incurred if a person uses condoms regularly over a 
period of one year is the cost of a condom, CCond, times the 
number of sexual encounters that person has in one year, 
NSE, so that  
 CP Cond SEC C N=  21 
Here we assume that people at risk of HIV have sex on 
average 100 times per year. 
Pre-exposure prophylaxis 
Under PreP we calculate the cost of keeping one HIV-
negative person on prophylaxis for one year so that 
 PreP Drugs Test PrePC C C T= +  22 
where CDrugs is the cost of the drugs for one year, CTest is 
the cost of testing a person for HIV and TPreP is the time 
between tests for a person on PreP to confirm that they 
have not yet been infected with HIV. 
 For PreP the cost of testing would exceed the cost of the 
drugs if the time between tests were less than  
 TestPrep
PreP
CT
C
=  23 
If the cost of PreP is about US$1 per day, or US$365 per 
year, and the cost of a test is about US$10 then the cost of 
testing would exceed the cost of drugs if testing were done 
more often than about 36 times per year.  
Male circumcision 
Male circumcision is different from the other interventions 
because it incurs a once-off cost which gives a degree of 
protection for life. For the individual cost and the short 
term cost we consider the once-off cost of MC. For the long 
term cost we spread the cost of one circumcision over the 
time for which a person is at risk of HIV, TRisk, so that the 
annual cost of MC is, in the long term, 
 MC Circ RiskC C T=  24 
and we assume that TRisk is ten years. 
Treating sexually transmitted infections 
The cost of treating a case of a sexually transmitted disease 
is more difficult to estimate. We need to know the 
incidence of STIs, ISTI, as this will determine the number of 
people who will present with an STI each year. The cost of 
treating all STIs is then  
 STI Treat STIC C I=  25 
where CTreat is the cost of treating one STI. There is 
evidence that syndromic management of STIs reduces the 
incidence of HIV but it should be noted that in the one trial 
that showed a significant reduction in the incidence of HIV 
the prevalence of all STIs increased over the course of the 
study in both the intervention and control arms.23 
Behaviour change 
For behaviour change interventions estimate CBC the cost 
per person covered of running a behaviour change 
programme for one year. 
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